Zepzelca Injection, Powder, Lyophilized, For Solution
Product Images NDC 68727-712

6 FDA label images from Jazz Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zepzelca (NDC 68727-712). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jazz Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Volume Calculation (Volume)

Volume Calculation (Volume)
A formula illustrating how to calculate the volume (mL) of ZEPZELCA injection based on body surface area (m²), individual dose (mg/m²), and concentration (0.5 mg/mL). This text panel provides dosing calculation guidance for the lurbinectedin powder for injection.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure of Lurbinectedin, the active ingredient in ZEPZELCA injection. The diagram shows the detailed molecular arrangement including rings, bonds, and functional groups characteristic of Lurbinectedin.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier survival probability plot comparing two treatment groups over time in months. The vertical axis shows survival probability percentage, and the horizontal axis shows time in months from 0 to 27. Two groups are plotted: Atezolizumab alone (black line) and Atezolizumab plus Lurbinectedin (gray line). Patient counts at risk are listed below the time axis. Censored data points are marked with plus signs on both curves.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A Kaplan-Meier survival curve chart showing probability percentage over time (months) for two treatment groups: Atezolizumab alone and Atezolizumab with Lurbinectedin. Data points include censored observations marked by plus signs. The chart includes a risk table indicating the number of patients at risk at various time points for each group.*
FDA Label Image

Carton (Carton)

Carton (Carton)
Packaging label for ZEPZELCA (lurbinectedin) injection, lyophilized powder for solution. Each single-dose vial contains 4 mg of lurbinectedin. The label indicates intravenous infusion only, with storage instructions and manufacturer information. Distributed by Jazz Pharmaceuticals, Inc., made in Spain.*
FDA Label Image

Vial (Vial)

Vial (Vial)
Label for ZEPZELCA (lurbinectedin) injection, powder, lyophilized for solution, 4 mg per vial for intravenous infusion. The label includes storage instructions to refrigerate at 2°C to 8°C, a hazard warning, and manufacturer information for Jazz Pharmaceuticals, Inc. It also states the vial is single-dose and unused portions should be discarded.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.